Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02339064 · ClinicalTrials.gov registry record · Phase 3

Infusion of Apomorphine: Long-term Safety Study

A Phase 3 study of Idiopathic Parkinson´s Disease, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
99
Enrollment target
18
Study locations

NCT02339064 is a Phase 3 study of Idiopathic Parkinson´s Disease that is active but no longer recruiting, run by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals. The registered enrollment target is 99 participants, below the 206-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (52% lower). The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02339064, a Phase 3 study of Idiopathic Parkinson´s Disease, is active but no longer recruiting, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
99 participants
Enrollment target
18
Study locations

Study Summary

This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

Conditions Studied

Idiopathic Parkinson´s Disease

Interventions

  • DRUG apomorphine infusion

Study Locations (18)

California

  • - Loma Linda
  • - Los Angeles
  • - Los Angeles

Colorado

  • - Aurora
  • - Englewood

Georgia

  • - Atlanta
  • - Augusta

Illinois

  • - Chicago
  • - Chicago

Arizona

  • - Phoenix

Florida

  • - Boca Raton

Kansas

  • - Kansas City

Michigan

  • - West Bloomfield

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2015-02
Est. Completion 2025-12
Phase Phase 3

Sponsor

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02339064

The ClinicalTrials.gov registry entry for NCT02339064 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (52% lower). The listed sponsor is MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 1 intervention - of which apomorphine infusion is the first listed.

NCT02339064 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT02339064 about?

NCT02339064 is a clinical study titled "Infusion of Apomorphine: Long-term Safety Study". This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therap...

What is the current status of trial NCT02339064?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2015-02. Estimated completion is 2025-12.

What conditions does trial NCT02339064 study?

This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease.

What interventions are being tested in trial NCT02339064?

The interventions under investigation include: apomorphine infusion (DRUG).

Who is sponsoring clinical trial NCT02339064?

This trial is sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02339064 being conducted?

This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Parkinson´s Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Parkinson´s Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.